Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives

被引:30
作者
Arigita, C
Luijkx, T
Jiskoot, W
Poelen, M
Hennink, WE
Crommelin, DJA
van der Ley, P
van Els, C
Kersten, GFA
机构
[1] Netherlands Vaccine Inst, Unit Res & Dev, NL-3720 AL Bilthoven, Netherlands
[2] Univ Utrecht, UIPS, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands
关键词
Neisseria meningitidis; vaccine; adjuvant;
D O I
10.1016/j.vaccine.2005.06.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Potent liposomal PorA formulations containing various lipopolysaccharide (LPS) derivatives were developed. The following adjuvants were compared: the commonly used aluminum phosphate (AlPO4), and three LPS like adjuvants: monophosphoryl lipid A (MPL), lipopolysaccharide (gaff LPS) and the less toxic LPS mutant lpxL1. The immunogenicity in mice was evaluated and compared with that against an outer membrane vesicle (OMV) vaccine. The IgG isotype distribution and bactericidal activity were determined. Furthermore, PorA specific proliferation of lymph node cells after immunization and restimulation in vitro was studied with selected formulations. Both AlPO4 and MPL were unable to improve the functional immunogenicity (i.e. bactericidal response) of liposomal PorA. Besides, when these adjuvants were used, the percentage of responders in the groups did not reach 100%. This was also observed with non adjuvated PorA-liposomes or OMV. Of the adjuvants studied, only galE LPS and lpxL1 LPS were capable of increasing the immunogenicity and avoid non responsiveness against PorA-liposomes. Importantly, the adjuvant activity of lpxL1 LPS was accompanied by an improved PorA specific proliferation of lymph node cells and a concomitant increase in IL-2 production. In conclusion and considering its lower toxicity, lpxL1 LPS adjuvated liposomes are superior to other formulations tested. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5091 / 5098
页数:8
相关论文
共 38 条
  • [1] WHOLE-CELL ELISA FOR TYPING NEISSERIA-MENINGITIDIS WITH MONOCLONAL-ANTIBODIES
    ABDILLAHI, H
    POOLMAN, JT
    [J]. FEMS MICROBIOLOGY LETTERS, 1987, 48 (03) : 367 - 371
  • [2] LIPOPOLYSACCHARIDE, LIPID-A, AND LIPOSOMES CONTAINING LIPID-A AS IMMUNOLOGICAL ADJUVANTS
    ALVING, CR
    [J]. IMMUNOBIOLOGY, 1993, 187 (3-5) : 430 - 446
  • [3] Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines
    Arigita, C
    Jiskoot, W
    Westdijk, J
    van Ingen, C
    Hennink, WE
    Crommelin, DJA
    Kersten, GFA
    [J]. VACCINE, 2004, 22 (5-6) : 629 - 642
  • [4] Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes
    Arigita, C
    Kersten, GFA
    Hazendonk, T
    Hennink, WE
    Crommelin, DJA
    Jiskoot, W
    [J]. VACCINE, 2003, 21 (9-10) : 950 - 960
  • [5] Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines
    Baldridge, JR
    Crane, RT
    [J]. METHODS, 1999, 19 (01) : 103 - 107
  • [6] CARTWRIGHT K, 2001, VACCINE, V29, P4347
  • [7] Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine
    Claassen, I
    Meylis, J
    vanderLey, P
    Peeters, C
    Brons, H
    Robert, J
    Borsboom, D
    vanderArk, A
    vanStraaten, I
    Roholl, P
    Kuipers, B
    Poolman, J
    [J]. VACCINE, 1996, 14 (10) : 1001 - 1008
  • [8] Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells
    de Jager, W
    te Velthuis, H
    Prakken, BJ
    Kuis, W
    Rijkers, GT
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (01) : 133 - 139
  • [9] Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine
    de Kleijn, E
    van Eijndhoven, L
    Vermont, C
    Kuipers, B
    van Dijken, H
    Rümke, H
    de Groot, R
    van Alphen, L
    van den Dobbelsteen, G
    [J]. VACCINE, 2001, 20 (3-4) : 352 - 358
  • [10] Immunogenicity and safety of monovalent P1.7h,4 meningococcal outer membrane vesicle vaccine in toddlers:: comparison of two vaccination schedules and two vaccine formulations
    de Kleijn, ED
    de Groot, R
    Lafeber, AB
    Labadie, J
    van Limpt, KCJP
    Visser, J
    Berbers, GAM
    van Alphen, L
    Rümke, HC
    [J]. VACCINE, 2000, 19 (9-10) : 1141 - 1148